PER 2.35% 8.7¢ percheron therapeutics limited

Pfizer hits brakes on DMD gene therapy, page-2

  1. 4,683 Posts.
    lightbulb Created with Sketch. 1086
    Yes i have asked the mods to delete my post...the 'fell over' bit was for another indication.

    More accurate status for DMD is below:

    The pharma giant also reported that ongoing discussions with the FDA have created a roadblock for their Phase III trial of a new gene therapy for Duchenne muscular dystrophy now dubbed fordadistrogene movaparvovec.

    My view still stands - we won't see GT solution for DMD anytime soon.

    FDA will make both Pfizer and Sarepta jump through some very expensive and time consuming hoops to prove GT safety and efficacy.

    Sarepta, Roche and Pfizer need to look at a more practical solution as a bridge until GT is further refined...and safe.

    Accumulate on weakness!

    .
    Last edited by Uboy: 05/05/21
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.7¢
Change
0.002(2.35%)
Mkt cap ! $78.43M
Open High Low Value Volume
8.6¢ 8.9¢ 8.5¢ $53.40K 614.3K

Buyers (Bids)

No. Vol. Price($)
1 49999 8.7¢
 

Sellers (Offers)

Price($) Vol. No.
8.9¢ 67263 1
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.